Efficiency of Using Vita-melatonin in Patients with Non-alcoholic Fatty Liver Disease in Combination with Chronic Pancreatitis and Type 2 Diabetes Mellitus

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Mar 31, 2021
DOI: https://doi.org/10.30841/2307-5112.1.2021.231929
Keywords:
non-alcoholic fatty liver disease, chronic pancreatitis, type 2 diabetes mellitus, treatment, melatonin,

##plugins.themes.bootstrap3.article.main##

Yelizaveta Sirchak
Uzhhorod National University, Ukraine
https://orcid.org/0000-0001-6738-0843
Vasyl Hryha
Uzhhorod National University, Ukraine
https://orcid.org/0000-0002-2616-2230
Vasyl Barani
Uzhhorod National University, Ukraine
Oleksandra Reho
Uzhhorod National University, Ukraine
https://orcid.org/0000-0002-8339-2171

Abstract

The objective: to analyze the effectiveness and feasibility of complex therapy with the use of a melatonin preparation in patients with nonalcoholic fatty liver disease (NAFLD) in combination with chronic pancreatitis (CP) and type 2 diabetes mellitus (DM).


Materials and methods. We examined 64 patients with NAFLD in combination with CP and type 2 diabetes (mean age – 48.9 ± 5.4 years). The control group included 20 practically healthy individuals: 12 (60.0 %) men and 8 (40.0 %) women (average age – 47.6 ± 5.8 years). The patients were divided into two groups depending on the prescribed treatment: Group I (n = 30) – patients received only basic therapy (BT), Group II (n = 34) – patients were prescribed melatonin in addition to BT (Vita-melatonin, firm PJSC «Kiev Vitamin Plant», Ukraine) at a dose of 3 mg per day 30 minutes before bedtime for 1 month. All patients with NAFLD in combination with CP and type 2 diabetes before and after treatment were examined by general clinical, anthropometric, instrumental and laboratory methods. To verify the diagnosis, attention was paid to the nature of the complaints, the medical history.


Results. The results of the study make it possible to recommend the melatonin preparation as part of the complex treatment of patients with NAFLD in combination with CP and type 2 diabetes due to its antioxidant, anti-inflammatory properties, as well as its ability to influence cognitive changes in these patients.


Conclusion. The drug melatonin (Vita-melatonin) is an effective, safe agent for the complex treatment of patients with NAFLD in combination with CP and type 2 diabetes. Normalization of the serum melatonin level in patients with NAFLD in combination with CP and type 2 diabetes with the use of melatonin leads to a decrease and / or normalization of the indicators of cognitive status in these patients.

##plugins.themes.bootstrap3.article.details##

How to Cite
Sirchak, Y., Hryha, V., Barani, V., & Reho, O. (2021). Efficiency of Using Vita-melatonin in Patients with Non-alcoholic Fatty Liver Disease in Combination with Chronic Pancreatitis and Type 2 Diabetes Mellitus. Family Medicine, (1), 39–46. https://doi.org/10.30841/2307-5112.1.2021.231929
Issue
No. 1 (2021)
Section
For practicing physicians
Copyright (c) 2021 Yelizaveta Sirchak, Vasyl Hryha, Vasyl Barani, Oleksandra Reho

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

Yelizaveta Sirchak, Uzhhorod National University

Yelizaveta S. Sirchak,

Department of Propaedeutics of Internal Diseases

Vasyl Hryha, Uzhhorod National University

Vasyl I. Hryha,

Department of Propaedeutics of Internal Diseases,

Department of Biochemistry, Pharmacology and Physical Methods of Treatment

Vasyl Barani, Uzhhorod National University

Vasyl Ye. Barani,

Department of Propaedeutics of Internal Diseases

Oleksandra Reho, Uzhhorod National University

Oleksandra Yu. Reho,

Department of Social Medicine and Hygiene

References

Васендин Д.В. Структурные изменения в печени при метаболическом синдроме / Д.В. Васендин // Ученые записки СПбГМУ им. акад. И.П. Павлова. – 2015. – № 4, Том ХХІІ. – С. 20–27.

Ивашкин В.Т. Диагностика и лечение неалкогольной жировой болезни печени: клинические рекомендации / В.Т. Ивашкина. – М.: МЕД-пресс-информ, 2015. – 32 с.

Неінвазивна діагностика фіброзу печінки у хворих із неалкогольною жировою хворобою печінки / [Ю.М. Степанов, Н.В. Недзвецька, В.Б. Ягмур та ін.] // Гастроентерологія. – 2017. – Том 51, № 3. – С. 188–195.

Неалкогольна жирова хвороба печінки: особливості метаболічних змін на різних етапах розвитку хвороби / [Ю.М. Степанов, Н.В. Недзвецька, В.Б. Ягмур, І.А. Кленіна] // Гастроентерологія. – 2018. – Том 52, № 1. – С. 13–18.

Неалкогольная жировая болезнь печени: сравнительная оценка подходов к диагностике и терапии в Российской Федерации и Китайской Народной Республике / [М.Ч. Семенистая, Фан Цзянь-гао, О.В. Величенко и др.] // Рос. Журн. Гастроэнтерол. Гепатол. колопроктол. – 2017. – № 27 (6). – С. 63–70.

Антиапоптотическое действие мелатонина при неалкогольном стеатогепатите, развивающемся при сахарном диабете 2-го типа / [С.С. Попов, А.Н. Пашков, И.Э. Есауленко и др.] // Клиническая эндокринология. – 2018. – № 63 (3). – С. 162–168.

Мелатонин – при диабете и ожирении показан / [С.В. Мичурина, А.В. Шурлыгина, А.Ю. Летягин и др.] // Наука из первых рук. – 2020. – № 2 (87). – С. 49–55.

Арушанян Э.Б. Значение мелатонина для деятельности печени / Э.Б. Арушанян, Е.В. Щетинин // Медицина. – 2018. – № 2. – С. 35–50.

EASL–EASD–EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease / European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) // Journal of Hepatology. – 2016. –V. 64. – P. 1388–1402.

Цукровий діабет 2 типу / [М.В. Гульчій, Л.Ф. Матюха, В.З. Нетяженко та інші.] // Адаптована клінічна настанова, заснована на доказах. – К., 2012. – 343 с.

Ахутина Т.В. Нейропсихологическое тестирование: обзор современных тенденций. К 110-летию со дня рождения А.Р. Лурия / Т.В. Ахутина, З.А. Меликян // Клиническая и специальная психология. – 2012. – № 2. – С. 1–20. www.psyjournals.ru/psyclin

Мамчур В.И. Мелатонин как вспомогательная терапия при COVID-19 / В.И. Мамчур, Д.С. Носивец, Е.В. Хомяк // Семейная медицина. – 2020. – №3(89). – С. 13–19.